ATE427317T1 - Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin- bindungsdomane - Google Patents
Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin- bindungsdomaneInfo
- Publication number
- ATE427317T1 ATE427317T1 AT02756777T AT02756777T ATE427317T1 AT E427317 T1 ATE427317 T1 AT E427317T1 AT 02756777 T AT02756777 T AT 02756777T AT 02756777 T AT02756777 T AT 02756777T AT E427317 T1 ATE427317 T1 AT E427317T1
- Authority
- AT
- Austria
- Prior art keywords
- neuregulin
- targeted
- heparin binding
- proteoglycan
- hybrid proteins
- Prior art date
Links
- 229920002971 Heparan sulfate Polymers 0.000 title abstract 2
- 229920000669 heparin Polymers 0.000 title abstract 2
- 229960002897 heparin Drugs 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 102000014413 Neuregulin Human genes 0.000 abstract 2
- 108050003475 Neuregulin Proteins 0.000 abstract 2
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 abstract 2
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 abstract 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108090000054 Syndecan-2 Proteins 0.000 abstract 1
- 230000008484 agonism Effects 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30856301P | 2001-07-31 | 2001-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE427317T1 true ATE427317T1 (de) | 2009-04-15 |
Family
ID=23194471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02756777T ATE427317T1 (de) | 2001-07-31 | 2002-07-31 | Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin- bindungsdomane |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7527794B2 (enExample) |
| EP (1) | EP1456239B1 (enExample) |
| JP (1) | JP4314113B2 (enExample) |
| AT (1) | ATE427317T1 (enExample) |
| AU (1) | AU2002322762B2 (enExample) |
| CA (1) | CA2455830C (enExample) |
| DE (1) | DE60231833D1 (enExample) |
| WO (1) | WO2003012045A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1824879B1 (en) * | 2004-07-09 | 2014-10-29 | Wayne State University | HYBRID PROTEINS WITH ErbB4 EXTRACELLULAR DOMAIN AND NEUREGULIN HEPARIN-BINDING DOMAIN FOR TARGETING |
| EP2197907A2 (en) * | 2007-10-15 | 2010-06-23 | Centre National De La Recherche Scientifique-CNRS | Cxcl12 gamma a chemokine and uses thereof |
| US9198952B2 (en) | 2008-09-22 | 2015-12-01 | The Brigham And Women's Hospital, Inc. | Compositions of and methods of using ligand dimers |
| WO2011119836A1 (en) | 2010-03-24 | 2011-09-29 | Massachusetts Institute Of Technology | Methods and compositions for cardioprotection and cardioregeneration |
| US20130072437A1 (en) * | 2010-05-28 | 2013-03-21 | Mind-Nrg Sa | Neuregulin isoforms,neuregulin polypeptides and uses thereof |
| JP2014520148A (ja) | 2011-06-20 | 2014-08-21 | セントルイス ユニバーシティ | 治療のための神経筋接合部への標的化 |
| US20130058871A1 (en) * | 2011-07-28 | 2013-03-07 | Howard Hughes Medical Institute | Method and system for mapping synaptic connectivity using light microscopy |
| CN104619727B (zh) * | 2012-06-25 | 2019-04-05 | 布里格姆及妇女医院股份有限公司 | 靶向治疗 |
| US9790264B2 (en) | 2012-06-25 | 2017-10-17 | The Brigham And Women's Hospital, Inc. | Compounds and methods for modulating pharmacokinetics |
| WO2016116477A1 (en) * | 2015-01-20 | 2016-07-28 | Universiteit Antwerpen | Neuregulin in the treatment of fibrotic disorders |
| WO2016123163A2 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| US12466865B2 (en) | 2019-01-03 | 2025-11-11 | The Board Of Trustees Of The University Of Illinois | Method and kit for treating a neurodegenerative disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8947791A (en) * | 1990-11-01 | 1992-05-26 | Scripps Research Institute, The | Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions |
| US5367060A (en) | 1991-05-24 | 1994-11-22 | Genentech, Inc. | Structure, production and use of heregulin |
| WO1993022424A1 (en) * | 1992-04-29 | 1993-11-11 | Amgen Inc. | RECOMBINANT STIMULATING FACTOR OF THE neu RECEPTOR |
| EP0663007A1 (en) | 1992-09-29 | 1995-07-19 | The President And Fellows Of Harvard College | Trophic factor having ion channel-inducing activity in neuronal cells |
| US6037329A (en) * | 1994-03-15 | 2000-03-14 | Selective Genetics, Inc. | Compositions containing nucleic acids and ligands for therapeutic treatment |
| AU6965696A (en) | 1995-09-05 | 1997-03-27 | Cambridge Neuroscience, Inc. | Analogs for specific oligosaccharide-neuregulin interactions and uses thereof |
| US6344436B1 (en) * | 1996-01-08 | 2002-02-05 | Baylor College Of Medicine | Lipophilic peptides for macromolecule delivery |
| CA2258721C (en) | 1996-07-12 | 2014-09-09 | Genentech, Inc. | Chimeric heteromultimer adhesins |
| DE69732711T2 (de) * | 1996-07-12 | 2006-03-16 | Genentech, Inc., South San Francisco | Gamma-heregulin |
| KR100195886B1 (ko) | 1996-11-01 | 1999-06-15 | 김상조 | 당뇨병 치료용 의약조성물 |
| WO1998043649A2 (en) | 1997-03-28 | 1998-10-08 | Otsuka Pharmaceutical Co., Ltd. | Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b¿6? |
| AU4469997A (en) | 1997-09-17 | 1999-04-05 | Urs Eppenberger | Heregulin-gamma |
| GB2363714B (en) | 1998-04-23 | 2004-03-03 | Vladimir Leko | Herbal composition and medicament against diabetes mellitus type II manufactured thereof |
| AU2322600A (en) | 1999-01-29 | 2000-08-18 | Kaneka Corporation | Processes for the preparation of (threo)-1,2-epoxy-3-amino-4-phenylbutane derivatives |
-
2002
- 2002-07-31 JP JP2003517223A patent/JP4314113B2/ja not_active Expired - Fee Related
- 2002-07-31 DE DE60231833T patent/DE60231833D1/de not_active Expired - Lifetime
- 2002-07-31 EP EP02756777A patent/EP1456239B1/en not_active Expired - Lifetime
- 2002-07-31 WO PCT/US2002/024053 patent/WO2003012045A2/en not_active Ceased
- 2002-07-31 AT AT02756777T patent/ATE427317T1/de not_active IP Right Cessation
- 2002-07-31 AU AU2002322762A patent/AU2002322762B2/en not_active Ceased
- 2002-07-31 US US10/485,206 patent/US7527794B2/en not_active Expired - Lifetime
- 2002-07-31 CA CA2455830A patent/CA2455830C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2455830A1 (en) | 2003-02-13 |
| EP1456239A2 (en) | 2004-09-15 |
| US20050107601A1 (en) | 2005-05-19 |
| EP1456239B1 (en) | 2009-04-01 |
| US7527794B2 (en) | 2009-05-05 |
| JP2005500052A (ja) | 2005-01-06 |
| CA2455830C (en) | 2012-10-09 |
| AU2002322762B2 (en) | 2008-10-16 |
| WO2003012045A2 (en) | 2003-02-13 |
| JP4314113B2 (ja) | 2009-08-12 |
| WO2003012045A3 (en) | 2004-07-01 |
| DE60231833D1 (de) | 2009-05-14 |
| EP1456239A4 (en) | 2005-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE427317T1 (de) | Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin- bindungsdomane | |
| NO20001600D0 (no) | Apolipoprotein A-1-agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser | |
| DE69738483D1 (de) | Polypeptide mit phytase-aktivität und sie kodierende nukleinsäuren | |
| NO20001599L (no) | Apolipoprotein A-1 agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser | |
| PL341524A1 (en) | Novel receptor coupled wih g protein | |
| BG104149A (bg) | Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение | |
| NZ595496A (en) | Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them | |
| ATE352626T1 (de) | Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren | |
| DE69637874D1 (de) | C-C CHEMOKIN REZEPTOR 3: CKR-3 ODER Eos-L2 | |
| EP1009814A4 (en) | KDR, A HUMAN TYROSIN KINASE RECEPTOR | |
| ATE354638T1 (de) | Menschlicher gewebsinhibitor von metalloproteinase-4 | |
| ATE323770T1 (de) | Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren | |
| WO2006017184A3 (en) | HYBRID PROTEINS WITH ErbB4 EXTRACELLULAR DOMAIN AND NEUREGULIN HEPARIN-BINDING DOMAIN FOR TARGETING | |
| EA199900522A1 (ru) | Полипептиды, кодируемые геном, подобным гену липазы человека, композиции и методы | |
| TR200200253T2 (tr) | Proteinlerin üretimi | |
| DE69929183D1 (de) | G-csf-rezeptoragonist-antikörper und methode zu ihrer isolierung mittels durchmusterung | |
| DE69634757D1 (de) | Vektor zur expression von n-terminal verlängerten proteinen in hefezellen | |
| Klatt et al. | The matrilin-3 VWA1 domain modulates interleukin-6 release from primary human chondrocytes | |
| BR0007816A (pt) | Fator de estimulação óssea | |
| WO2000055192A3 (de) | Hämocyanin und dafür kodierende nukleinsäuresequenz | |
| ATE317896T1 (de) | Polypeptide mit glucanotransferase aktivität und dafür kodierende nukleinsäuren | |
| ATE260339T1 (de) | Antikörper gegen menschliches restrictin | |
| MXPA02011938A (es) | Adn que codifica para un receptor de histamina de mamifero del subtipo h4. | |
| ATE362531T1 (de) | Interne ribosom eintrittstelle (ires), vektor der diesen enthaltet und dessen therapeutische verwendung | |
| Bonaldo et al. | Efficient Expression of Chicken α (VI) Collagen Chain in Transiently Transfected Mammalian Cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |